ACCESS Through OTC Innovation Act
- Bill Number
- H.R. 6868
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-12-18: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-01-22T15:13:48Z
AI-Generated Summary
Purpose
The legislation aims to streamline the regulatory process for over-the-counter (OTC) drugs by requiring the Secretary of Health and Human Services (HHS) to use the least burdensome methods when evaluating certain requests for administrative orders. This promotes innovation in OTC monograph drugs—products like pain relievers or sunscreens that are approved through a standardized "monograph" system rather than individual applications—while maintaining safety and effectiveness standards.
Key Provisions
- Least Burdensome Approach: When assessing if an OTC drug is "generally recognized as safe and effective" (a legal standard meaning experts widely agree it's safe for consumer use without a prescription), HHS must apply the simplest appropriate methods to support the request, such as relying on existing published studies if sufficient.
- Mandatory Meetings with Requestors: If published data is inadequate, HHS must hold a meeting with the drug maker (requestor) upon a reasonable written request. The meeting focuses on advising on needed evidence, including potential study designs and sizes to prove safety and effectiveness.
- Documentation Requirements: HHS must prepare and share meeting minutes with the requestor, and include written recommendations on study parameters plus a discussion summary in the official administrative record (the documented file used for decision-making).
- Limitations: The new rules do not change the basic requirements for submitting a complete request or the core criteria for deeming a drug safe and effective.
Significant Changes to Existing Law
- Amends Section 505G of the Federal Food, Drug, and Cosmetic Act (which governs OTC drug monographs) by adding a new subsection (q).
- Shifts from potentially rigid review processes to a more flexible, guidance-oriented one, emphasizing efficiency without altering safety thresholds.
- Redesignates the existing subsection (q) as (r) to accommodate the insertion.
Potential Impacts
- Government Agencies: The Food and Drug Administration (FDA, under HHS) may face increased administrative workload from mandatory meetings and record-keeping, but this could lead to faster, more efficient reviews overall.
- Citizens: Could result in quicker availability of new or improved OTC drugs, enhancing consumer access to affordable self-care options like topical treatments or allergy remedies, potentially improving health equity and safety through innovation.
- International Relations: Minimal direct impact, though it may indirectly support U.S. pharmaceutical competitiveness by easing domestic OTC development, which could influence global trade in consumer health products.
Main Stakeholders Affected
- Pharmaceutical Industry: Drug manufacturers, especially those developing OTC products, benefit from clearer guidance and reduced barriers to approval, encouraging investment in innovation.
- Government Regulators: HHS and FDA must adapt procedures to provide more proactive support, balancing efficiency with oversight.
- Consumers: Everyday users of OTC drugs gain from potentially faster access to safe, effective options, supporting self-care without needing doctor visits.
- Healthcare Providers: May see indirect benefits through reduced demand on prescription services for common ailments.
Notable Legal, Constitutional, or Political Implications
- Legal: Reinforces the "least burdensome" principle already in FDA regulations (e.g., from the 1997 FDA Modernization Act) but applies it specifically to OTC administrative orders, ensuring decisions are evidence-based without compromising the statutory definition of safety and effectiveness. The "rule of construction" clause prevents challenges to existing review standards.
- Constitutional: No apparent issues; it aligns with Congress's authority to regulate interstate commerce and public health under the Commerce Clause, promoting administrative efficiency without infringing on due process.
- Political: Positions as pro-innovation and consumer-focused, potentially appealing across party lines by reducing regulatory hurdles while upholding safety—could influence broader debates on FDA reform and drug accessibility.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Recent Actions
- 2025-12-18: Referred to the House Committee on Energy and Commerce.
- 2025-12-18: Introduced in House
- 2025-12-18: Introduced in House
Bill Versions
- Advancing Consumer Choice, Equity, Safety, and Self-Care Through OTC Innovation Act — issued 2025-12-18 — PDF (4 pages)